- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02437279
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)
Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Patients with stage III melanoma with palpable disease, naïve for CTLA-4/PD-1/PD-L1 immunotherapy, will be treated either post-surgery for 12 weeks with the combination of ipilimumab+nivolumab or in a split design for 6 weeks upfront surgery and for 6 weeks postsurgery. It is a two-arm Phase 1b feasibility trial consisting of 20 patients, 10 in each arm.
At different timepoints tumor biopsies and blood for PBMCs will be taken for translational research. Also scans will be done on specific timepoints.
The study will be held to determine safety, feasibility, and the immune-activating capacity of short-term combined neo-adjuvant and adjuvant ipilimumab + nivolumab. And to determine relapse free survival (RFS), any late adverse events, pharmacokinetics/pharmacodynamics, and the correlation between RFS and changes in neo-antigen specific T cell response.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
NH
-
Amsterdam, NH, Nederländerna, 1066CX
- Netherlands Cancer Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults at least 18 years of age
- World Health Organization (WHO) Performance Status 0 or 1
- Histologically confirmed stage IIIB metastatic cutaneous melanoma, palpable disease (non-transit only) of the axilla or groin
- Patient willing to undergo triple tumor biopsies during screening and in case of disease progression
- No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1
- No immunosuppressive medications within 6 months prior study inclusion
- Presence of at least two of the defined HLA alleles (Table 1, see appendix)
Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils
≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN
- normal LDH
- Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
- Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of ipilimumab+nivolumab
- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product
- Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception
Exclusion Criteria:
- Distantly metastasized melanoma
- Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
- Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy
- Radiotherapy prior or post surgery within this trial
- Patients will be excluded if they are positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
- Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Allergies and Adverse Drug Reaction
- History of allergy to study drug components
- History of severe hypersensitivity reaction to any monoclonal antibody
- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events;
- Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion
- Pregnant or nursing.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Arm A
Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
|
|
Aktiv komparator: Arm B
A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
Tidsram: 12 weeks from baseline
|
To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA).
Proteasomal degradation and peptide presentation in HLA will be predicted in silico.
MHC-tetramer staining containing the predicted peptides will be done as described before [2].
In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed.
Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).
|
12 weeks from baseline
|
Safety as measured by SUSARs.
Tidsram: 12 weeks from baseline
|
12 weeks from baseline
|
|
The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
Tidsram: 12 weeks from baseline
|
To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA).
Proteasomal degradation and peptide presentation in HLA will be predicted in silico.
MHC-tetramer staining containing the predicted peptides will be done as described before [2].
In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed.
Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).
|
12 weeks from baseline
|
Feasibility as measured adherence to the timelines in the study protocol.
Tidsram: 12 weeks from baseline
|
12 weeks from baseline
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Recurrence Free Survival, as determined according to RECIST 1.1 criteria.
Tidsram: Until progression, median 10 months.
|
Until progression, median 10 months.
|
Rate of adverse events and late adverse events
Tidsram: Until end of follow-up, median 3 years.
|
Until end of follow-up, median 3 years.
|
Type of adverse events and late adverse events
Tidsram: Until end of follow-up, median 3 years.
|
Until end of follow-up, median 3 years.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Christian Blank, MD PhD, The Netherlands Cancer Institute
Publikationer och användbara länkar
Allmänna publikationer
- Versluis JM, Reijers ILM, Rozeman EA, Menzies AM, van Akkooi ACJ, Wouters MW, Ch'ng S, Saw RPM, Scolyer RA, van de Wiel BA, Schilling B, Long GV, Blank CU. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021 May;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Epub 2021 Mar 15.
- Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021 Feb;27(2):256-263. doi: 10.1038/s41591-020-01211-7. Epub 2021 Feb 8.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroendokrina tumörer
- Nevi och melanom
- Melanom
- Molekylära mekanismer för farmakologisk verkan
- Antineoplastiska medel
- Antineoplastiska medel, immunologiska
- Immune Checkpoint-hämmare
- Nivolumab
- Ipilimumab
Andra studie-ID-nummer
- N14OPC
- CA209-278 (Annat bidrag/finansieringsnummer: BMS)
- NL51280.031.14 (Registeridentifierare: CCMO register)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Stadium III Hudmelanom
-
Elizabeth Buchbinder, MDGenentech, Inc.RekryteringSteg IV melanom | Kliniskt stadium III kutant melanom AJCC v8 | Inoperabelt stadium III kutant melanom | Inoperabelt stadium IV kutant melanomFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringMetastaserande melanom | Ooperabelt melanom | Kliniskt stadium III kutant melanom AJCC v8 | Patologiskt stadium III kutant melanom AJCC v8 | Kliniskt stadium IV kutant melanom AJCC v8 | Patologiskt stadium IV kutant melanom AJCC v8Förenta staterna
-
Scancell LtdRekryteringMelanom (hud) | Malignt melanom | Melanom Steg IV | Melanom stadium IIIStorbritannien
-
Dana-Farber Cancer InstitutePartner Therapeutics (PTx)IndragenMetastaserande melanom | Ooperabelt melanom | Steg IV melanom | Steg III melanomFörenta staterna
-
MelanomaPRO, RussiaRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom in Situ | Melanom, OkulärRyska Federationen
-
University of California, IrvineGlaxoSmithKlineAvslutadOoperabelt melanom | Steg IV melanom | Steg III melanomFörenta staterna
-
NewLink Genetics CorporationAvslutadMetastaserande melanom | Steg IV melanom | Steg III melanomFörenta staterna
-
University of Colorado, DenverMerck Sharp & Dohme LLCAktiv, inte rekryterandeSteg IV melanom | Avancerat melanom | Steg III melanomFörenta staterna
-
UNC Lineberger Comprehensive Cancer CenterGlaxoSmithKlineAvslutadOoperabelt melanom | Steg IV melanom | Steg III melanom | BRAF Mutant MelanomFörenta staterna
-
Emory UniversityGenentech, Inc.Aktiv, inte rekryterandeSteg IV Hudmelanom | Stadium IIIB Hudmelanom | Stadium IIIC Hudmelanom | Ooperabelt melanom | Steg III melanom | Stadium IIIA Hudmelanom | Kutant melanom, stadium III | Kutant melanom, stadium IVFörenta staterna
Kliniska prövningar på Surgery of the tumor
-
Larissa McGarrity, Ph.D.Har inte rekryterat ännu
-
University Hospital, Clermont-FerrandOkänd
-
Memorial Sloan Kettering Cancer CenterAvslutadFamiljer eller anhöriga till patienter som behandlas vid MSKCC för icke-kutana skivepitelcancer i | Övre matsmältningskanalenFörenta staterna
-
Medical College of WisconsinAvslutadKommunikation | PatientengagemangFörenta staterna
-
Canterbury Christ Church UniversityAvslutad
-
Boston University Charles River CampusRekryteringMentala störningar | Sysselsättning | Anställning, Support | MetakognitionFörenta staterna
-
Ankara Yildirim Beyazıt UniversityAvslutadOsteoporos | Hälsosam livsstil | UniversitetsstudenterKalkon
-
Skin Analytics LimitedInnovate UKAvslutad
-
Skin Analytics LimitedAvslutadBasalcellscancer | Skivepitelcancer | Malignt hudmelanom T0Förenta staterna, Italien
-
Skin Analytics LimitedInnovate UKAvslutad